Metastases to the pituitary gland are a rare finding, with breast and lung being the most common metastases in this anatomical region. Pituitary melanoma metastases reports are thus sparse, and both diagnosis and treatment are challenging. We present the case of a 66-year-old woman with pituitary melanoma metastasis who presented with symptoms of anterior pituitary dysfunction and headache. These symptoms were difficult to manage medically until gross total resection and immunotherapy were carried out. At 17 months post-operative, there was no progression of the underlying disease. A review of the published literature was performed for all the histologically confirmed pituitary melanoma metastases, as well as their clinical presentation, diagnosis, and treatment workout. Our literature review included 18 published cases: the median age was 62, 68% were male, and the median time of melanoma diagnosis to pituitary metastasis diagnosis was 25 months. The most common symptoms were anterior pituitary deficiency, visual disturbances, headache, cranial nerve palsy, and diabetes insipidus. In terms of management, surgery, radiotherapy, and chemotherapy were used alone or in combination. The median overall survival was 9.5 months. These metastases present a great diagnostic and therapeutic challenge since the symptoms are non-specific and there are no available treatment guidelines. Surgery to decompress the adjacent structures allows for symptomatic control and a better quality of life.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753814 | PMC |
http://dx.doi.org/10.7759/cureus.76266 | DOI Listing |
Cureus
December 2024
Neurological Surgery, Hospital Central do Funchal, Funchal, PRT.
Metastases to the pituitary gland are a rare finding, with breast and lung being the most common metastases in this anatomical region. Pituitary melanoma metastases reports are thus sparse, and both diagnosis and treatment are challenging. We present the case of a 66-year-old woman with pituitary melanoma metastasis who presented with symptoms of anterior pituitary dysfunction and headache.
View Article and Find Full Text PDFEClinicalMedicine
January 2025
Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Background: Due to limited data on managing immunotherapy-induced secondary adrenal insufficiency (SAI) in melanoma survivors, this study investigated its management strategies and outcomes.
Methods: This retrospective cohort study analyzed melanoma patients treated with immune checkpoint inhibitors (ICIs) with SAI (Mel_SAI, n = 161), without SAI (Mel_CON, n = 168), and patients with pituitary adenoma-related SAI (Pit_SAI, n = 106) at our institution from January 2013 to November 2023. We compared glucocorticoid management patterns, quality of life using distress scores, and the impact of different glucocorticoid types on survival outcomes using Kaplan-Meier analysis.
JCEM Case Rep
November 2024
Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona 60126, Italy.
J Neurol Surg B Skull Base
December 2024
Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
The lateral supraorbital (LSO) approach is a less-invasive alternative to the pterional craniotomy that provides rapid transsylvian access. Establishing familiarity with the LSO technique and its features as compared with other anterolateral approaches is an important component of advanced skull base training. We present a step-by-step demonstration of the LSO approach using cadaveric dissection in a manner that is digestible for trainees at various levels.
View Article and Find Full Text PDFCureus
September 2024
Nephrology, Middletown Medical, Middletown, USA.
Immune checkpoint inhibitors, such as pembrolizumab, have transformed cancer therapy by enhancing the immune system's ability to combat tumors, but they can also lead to immune-related adverse events, including adrenal insufficiency. This case report presents a 52-year-old male with a history of malignant melanoma who developed adrenal insufficiency after four months of pembrolizumab therapy. The patient was admitted with symptoms of malaise, vomiting, abdominal pain, and poor appetite.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!